Paragon Care Limited · ASX:PGC
Paragon Care — Investor Presentation (August 2025)
21 slides from Paragon Care's investor presentation, Aug 27, 2025
Slide 1: Annual Financial Results Investor Presentation
Annual Financial Investor Presentation Results Year Ended 30 June 2025 ParagonCare Limited - ASX PGC
Slide 2: Disclaimer
Disclaimer This document has been prepared by Paragon Care Limited ACN 064 551 426 (ASX: PGC) (ParagonCare or the Company) (Presentation). The material in this Presentation contains general background information about ParagonCare and its current activities as at the date of this Presentation. The i
Slide 3: Overview of ParagonCare
Overview of ParagonCare
Slide 4: Strategic Overview
Strategic Overview ParagonCare is a leading distribution network for all APAC providers of healthcare. We achieve this through a combination of customer focus, our extensive product range, knowledge-based solutions, and “best in class” logistics and technology. Our Strategy Our Vision Be a diversifie
Slide 5: Board members
Board members David Collins Carmen Riley Peter Lacaze John Walstab Peter Egglestone Managing Director Chief Executive Officer Chairman Non-Executive Director Non-Executive Director David Collins is the Managing Director Carmen Riley was appointed as CEO on Peter Lacaze is the Chairman and 28.5% John
Slide 6: ParagonCare APAC
ParagonCare APAC Presenters: ParagonCare is a leading distribution network for all APAC providers of healthcare. ParagonCare operates across 7 countries in the APAC region and is continuing to pursue new markets. ParagonCare offers distribution services in Wholesale, OEM JAPAN KOREA and Medical Devi
Slide 7: Channels to Market
Channels to Market Medical Contract Clinical Wholesale Technology Logistics Manufacturing • Pharmacy • OEM Capital • Pharmacy • Blood Reagents Markets • Medical Consumables • OEM Devices • Consumables • Contract Manufacturing • Complementary Medicine • Surgical Robotics • Devices • Re-Labelling • Su
Slide 8: Dedicated Business Units
Dedicated Business Units Business Development - Category Management - Customer and Supplier Relationships Pharmacy Hospitals & Aged & Complementary Dental Vision Aesthetics Private OEM Capital Robotics Orthopaedics Service Manufacturing Contract Governments Primary Care Medicine Label Equipment & Di
Slide 9: Year in review
Year in review Operational Highlights: New agencies signed • CMR • Coreline Soft After the acquisition of Oborne by CH2 and then the merger of CH2 with • Medsio ParagonCare in 2024, we launched our 3-2-1 strategic initiative. Three • Swift MR Business, Two Years, One Team. Aligning our entire team t
Slide 10: FY25 Financials Results Key Highlights
FY25 Financials Results Key Highlights
Slide 11: Annual Performance Snapshot
Annual Performance Snapshot FY25 Underlying* $3.6+ billion $95.2 million $31.2 million Revenue EBITDA Net Profit After Tax FY25 Statutory $3.6+ billion $88.5 million $20.6 million Revenue EBITDA Net Profit After Tax * FY25 Underlying EBITDA results reflect a full year of the consolidated contributio
Slide 12: FY25 P&L
FY25 P&L: Commentary Underlying & Statutory Revenue growth was driven by: $m FY25 FY24 Var $ Var % Wholesale sales $3.0b (up 8%) Underlying & Proforma Profit and Loss* • Total Pharmacy sales of $2.8 billion reflects annual growth of 11.6%. Revenue 3,613.9 3,336.3 277.6 8.3% Coming off the back of 24
Slide 13: FY25 P&L
FY25 P&L: Commentary Underlying & Statutory Revenue growth was driven by: $m FY25 FY24 Var $ Var % Contract Logistics sales $336m (up 25%) Underlying & Proforma Profit and Loss* • Growth of 25% to $336m with further upside in FY26 benefiting from the implementation of a large-scale contract with Owe
Slide 14: FY25 P&L
FY25 P&L: Commentary Underlying & Statutory Gross Margin and Expenses: $m FY25 FY24 Var $ Var % Gross Margin $324m (up 8%) Underlying & Proforma Profit and Loss* • On an underlying basis, GM of $324m was an increase of $25m (8%) on the prior year. Gross Margin % was consistent year-on-year across Re
Slide 15: FY25 Balance Sheet
FY25 Balance Sheet: Statutory Commentary $m FY25 FY24 Var $ Var % Working capital was impacted by a retail pharmacy group of 103 sites delaying payments. We have entered into a subsequent payment Receivables 402.7 346.0 56.7 16% arrangement and maintain our assessment, whilst it is putting a drag on
Slide 16: FY25 Cash Flow & Net Debt
FY25 Cash Flow & Net Debt: Statutory $m FY25 FY24 Var $ Var % Operating cash flows 36.4 65.6 (29.2) (44%) Finance Costs (33.2) (16.2) (16.9) (104%) Commentary Tax (paid) (14.6) (4.9) (9.7) 198% Operating cash flows significantly impacted by the Retail Pharmacy Group receivables owing of $57m. We exp
Slide 17: Australia and New Zealand Overview
Australia and New Zealand Overview Revenue growth in line with expectations: Annual growth in Pharmacy of 11.6% within Australia continues to underpin topline performance within the region. Capital and Service has experienced some headwinds across the region due lack of government spending in hospit
Slide 18: Asia Overview
Asia Overview Revenue growth in line with expectations: Growth continues to be driven by the Aesthetics business which grew strongly due to new products and increased promotional activity. Imaging business was solid which offset lower service revenue - the service business reduces each year as produ
Slide 19: Executing on the integration plan
Executing on the integration plan DFV, REM, Enhanced Closure of New Business New Brisbane site ISO14001 and GMP project to Balance of Engagement with Surgical ordering platform Roseberry, Units launched: project underway. ISO 9001 expand our required Australia all key business specialities, for Fren
Slide 20: FY26 Outlook
FY26 Outlook Key focus: Focus on our 3-2-1 Strategy • Strategic focus on “One Team” way of doing business, investing in our people and complete the initial 3-2-1 strategy. “It’s been an exciting and challenging year in the business, as we not only • Continued execution on the integration plan for th
Slide 21: Thank you
Thank you